AU670962B2 - Method for antagonizing inositol 1,4,5-triphosphate - Google Patents
Method for antagonizing inositol 1,4,5-triphosphate Download PDFInfo
- Publication number
- AU670962B2 AU670962B2 AU48417/93A AU4841793A AU670962B2 AU 670962 B2 AU670962 B2 AU 670962B2 AU 48417/93 A AU48417/93 A AU 48417/93A AU 4841793 A AU4841793 A AU 4841793A AU 670962 B2 AU670962 B2 AU 670962B2
- Authority
- AU
- Australia
- Prior art keywords
- document
- international
- date
- search
- inositol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/795—Polymers containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Polyurethanes Or Polyureas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95239392A | 1992-09-28 | 1992-09-28 | |
| US952393 | 1992-09-28 | ||
| PCT/US1993/008168 WO1994007507A1 (en) | 1992-09-28 | 1993-08-30 | Method for antagonizing inositol 1,4,5-triphosphate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU4841793A AU4841793A (en) | 1994-04-26 |
| AU670962B2 true AU670962B2 (en) | 1996-08-08 |
Family
ID=25492868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU48417/93A Ceased AU670962B2 (en) | 1992-09-28 | 1993-08-30 | Method for antagonizing inositol 1,4,5-triphosphate |
Country Status (13)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996000586A2 (en) * | 1994-06-30 | 1996-01-11 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Methods for treating cell proliferative disorders by modulating signal transduction |
| JPH11503110A (ja) | 1995-02-17 | 1999-03-23 | スミスクライン・ビーチャム・コーポレイション | Ｉｌ−８受容体拮抗剤 |
| US5780483A (en) * | 1995-02-17 | 1998-07-14 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
| US6083920A (en) * | 1995-12-21 | 2000-07-04 | Ayurcore, Inc. | Compositions for modulating intracellular inositol trisphosphate concentration |
| US6005008A (en) * | 1996-02-16 | 1999-12-21 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
| US6262113B1 (en) | 1996-03-20 | 2001-07-17 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
| US6211373B1 (en) | 1996-03-20 | 2001-04-03 | Smithkline Beecham Corporation | Phenyl urea antagonists of the IL-8 receptor |
| KR20000022274A (ko) * | 1996-06-27 | 2000-04-25 | 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 | Il-8 수용체 길항제 |
| IL127667A0 (en) | 1996-06-27 | 1999-10-28 | Smithkline Beecham Corp | IL-8 receptor antagonists |
| WO2002038140A2 (en) * | 2000-11-09 | 2002-05-16 | Contrimmune Biotechnology Inc | Therapeutic uses for ip3 receptor-mediated calcium channel modulators |
| MX2014002535A (es) | 2011-09-02 | 2015-07-17 | Univ Columbia | Inhibidores de camkii, ip3r, calcineurina, p38 y mk2/3 para tratar las alteraciones metabolicas de la obesidad. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB781479A (en) * | 1953-08-27 | 1957-08-21 | Ciba Ltd | New polyureas and process for making them |
| US5276182A (en) * | 1990-07-09 | 1994-01-04 | The Dow Chemical Company | Process for preparing polyurea oligomers |
-
1993
- 1993-08-30 EP EP93921252A patent/EP0661982A1/en not_active Ceased
- 1993-08-30 WO PCT/US1993/008168 patent/WO1994007507A1/en not_active Application Discontinuation
- 1993-08-30 KR KR1019950701166A patent/KR950703347A/ko not_active Ceased
- 1993-08-30 CA CA002145681A patent/CA2145681A1/en not_active Abandoned
- 1993-08-30 JP JP6509054A patent/JPH08502068A/ja active Pending
- 1993-08-30 AU AU48417/93A patent/AU670962B2/en not_active Ceased
- 1993-08-30 NZ NZ256178A patent/NZ256178A/en unknown
- 1993-08-30 HU HU9500891A patent/HUT70192A/hu unknown
- 1993-09-21 ZA ZA936978A patent/ZA936978B/xx unknown
- 1993-09-22 IL IL107066A patent/IL107066A/en not_active IP Right Cessation
- 1993-09-22 TW TW082107787A patent/TW260663B/zh active
- 1993-09-27 MX MX9305933A patent/MX9305933A/es unknown
-
1995
- 1995-03-27 NO NO951163A patent/NO951163L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA936978B (en) | 1994-04-18 |
| HU9500891D0 (en) | 1995-05-29 |
| WO1994007507A1 (en) | 1994-04-14 |
| IL107066A (en) | 1998-01-04 |
| TW260663B (enrdf_load_stackoverflow) | 1995-10-21 |
| AU4841793A (en) | 1994-04-26 |
| IL107066A0 (en) | 1993-12-28 |
| KR950703347A (ko) | 1995-09-20 |
| HUT70192A (en) | 1995-09-28 |
| NO951163D0 (no) | 1995-03-27 |
| JPH08502068A (ja) | 1996-03-05 |
| NZ256178A (en) | 1997-03-24 |
| CA2145681A1 (en) | 1994-04-14 |
| NO951163L (no) | 1995-03-27 |
| MX9305933A (es) | 1994-04-29 |
| EP0661982A1 (en) | 1995-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU670962B2 (en) | Method for antagonizing inositol 1,4,5-triphosphate | |
| Leysen et al. | Serotonergic component of neuroleptic receptors | |
| Laduron et al. | In vitro and in vivo binding characteristics of a new long-acting histamine H1 antagonist, astemizole. | |
| Browning et al. | Pharmacological characterization of human recombinant melatonin mt1 and MT2 receptors | |
| Merlos et al. | Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF) | |
| DE69908414T2 (de) | Kombinationen von ileumgallensäuretransports inhibitoren und cholesteryl ester transfer protein inhibitoren | |
| Mendelsohn et al. | Phencyclidine receptors in rat brain cortex | |
| Hanson et al. | UK‐78,282, a novel piperidine compound that potently blocks the Kv1. 3 voltage‐gated potassium channel and inhibits human T cell activation | |
| CA2078572A1 (en) | Human neuronal nicotinic acetylcholine receptor compositions and methods employing same | |
| El-Fakahany et al. | Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain | |
| Forray et al. | On the involvement of multiple muscarinic receptor subtypes in the activation of phosphoinositide metabolism in rat cerebral cortex. | |
| Nagasawa et al. | . beta.-Substituted cysteines as sequestering agents for ethanol-derived acetaldehyde in vivo | |
| Aricioglu et al. | Effect of agmatine on the development of morphine dependence in rats: potential role of cAMP system | |
| Kostowski et al. | The abilities of 5-HT3 receptor antagonist ICS 205-930 to inhibit alcohol preference and withdrawal seizures in rats | |
| Church et al. | Interactions of dextromethorphan with theN-methyl-d-aspartate receptor-channel complex: single channel recordings | |
| Boyson et al. | Effects of chronic administration of neuroleptic and anticholinergic agents on densities of D2 dopamine and muscarinic cholinergic receptors in rat striatum. | |
| Rowan et al. | Neurophysiological effects of buspirone and isapirone in the hippocampus: comparison with 5-hydroxytryptamine | |
| Syvälahti et al. | Decrease in the number of rat brain dopamine and muscarinic receptors after chronic alcohol intake | |
| Purcell et al. | Characterisation of a functional polyamine site on rat mast cells: association with a NMDA receptor macrocomplex | |
| Thayer et al. | The interaction of dihydropyridine calcium channel blockers with calmodulin and calmodulin inhibitors. | |
| Greenberg et al. | Phenytoin interacts with calcium channels in brain membrances | |
| Harris et al. | Effects of dihydropyridine derivatives and anticonvulsant drugs on [3H] nitrendipine binding and calcium and sodium fluxes in brain | |
| Baumgold et al. | Pharmacological differences between muscarinic receptors coupled to phosphoinositide turnover and those coupled to adenylate cyclase inhibition | |
| Mei et al. | Pharmacological characterization of the M1 muscarinic receptors expressed in murine fibroblast B82 cells. | |
| Araujo et al. | Characterization of [3H] AF‐DX 116 binding sites in the rat brain: Evidence for heterogeneity of muscarinic‐M2 receptor sites |